{
  "id": 5317,
  "text": "J Clin Oncol 2007;25:2804-2810.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17502627.136.Eifel PJ, Winter K, Morris M, et al.Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: J Clin Oncol 2007;25:2804-2810.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17502627.136.Eifel PJ, Winter K, Morris M, et al.Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据现有的研究进展，高危宫颈癌的治疗方法对比中，一项辐射治疗肿瘤学组（RTOG）90-01试验的更新结果显示，盆腔放疗联合同步化疗与单独的盆腔及主动脉旁放疗相比，在改善患者存活率和疾病控制方面更具有优势。具体来说，研究表明，同步化疗能够显著提高放疗的效果，尤其是在控制远处转移方面表现突出。这种联合治疗方案不仅可以增强局部治疗作用，还可以通过化疗对潜在的微转移病灶提供系统性的支持，从而降低复发风险。\n\n然而，这种治疗方式可能伴随一定的毒性增加，例如血液毒性和胃肠道反应，因此在实施治疗时需要根据患者的具体情况进行谨慎评估和优化管理，以最大限度提高疗效并减少副作用。总体而言，盆腔放疗联合同步化疗已成为治疗高危宫颈癌的有效标准之一，并在临床实践中得到广泛应用。",
  "query": "高危宫颈癌的治疗中，盆腔放疗联合同步化疗与盆腔及主动脉旁放疗的比较有何研究进展？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 高危宫颈癌的治疗中，盆腔放疗联合同步化疗与盆腔及主动脉旁放疗的比较有何研究进展？\n\n<reference text>: J Clin Oncol 2007;25:2804-2810.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17502627.136.Eifel PJ, Winter K, Morris M, et al.Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据现有的研究进展，高危宫颈癌的治疗方法对比中，一项辐射治疗肿瘤学组（RTOG）90-01试验的更新结果显示，盆腔放疗联合同步化疗与单独的盆腔及主动脉旁放疗相比，在改善患者存活率和疾病控制方面更具有优势。具体来说，研究表明，同步化疗能够显著提高放疗的效果，尤其是在控制远处转移方面表现突出。这种联合治疗方案不仅可以增强局部治疗作用，还可以通过化疗对潜在的微转移病灶提供系统性的支持，从而降低复发风险。\n\n然而，这种治疗方式可能伴随一定的毒性增加，例如血液毒性和胃肠道反应，因此在实施治疗时需要根据患者的具体情况进行谨慎评估和优化管理，以最大限度提高疗效并减少副作用。总体而言，盆腔放疗联合同步化疗已成为治疗高危宫颈癌的有效标准之一，并在临床实践中得到广泛应用。"
}